推荐产品
product name
L-脯氨酸, Vetec™, reagent grade, ≥99%
等級
reagent grade
產品線
Vetec™
化驗
≥99%
形狀
powder
顏色
white
mp
228 °C (dec.) (lit.)
SMILES 字串
OC(=O)[C@@H]1CCCN1
InChI
1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
InChI 密鑰
ONIBWKKTOPOVIA-BYPYZUCNSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
法律資訊
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
Daniel R Knight et al.
Applied and environmental microbiology, 81(1), 119-123 (2014-10-19)
Clostridium difficile is an important enteric pathogen of humans and the cause of diarrhea and enteritis in neonatal pigs. Outside Australia, prevalence in piglets can be up to 73%, with a single PCR ribotype (RT), 078, predominating. We investigated the
Salvatore Petta et al.
Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门